Core Insights - The company rebuilt its commercial team, increasing sales personnel from approximately 60 to over 90 to address high clinic attrition, showing results in stabilizing the network by Q4 2025 [1] - The restructuring of the commercial organization focused on servicing existing accounts and driving new clinic starts [1] - Procedure revenue declines were primarily due to higher-than-historical clinic attrition, which accelerated to high single digits in 2024 compared to the typical 5% rate [1] - The strategic focus has shifted towards maximizing value from top-tier clinics by refining contract models and incentive structures for long-term practitioner retention [1] - Operational discipline was enhanced through upgraded data analytics and internal systems, enabling more consistent execution and scalability [1] - Dietary supplement growth of 16% served as a critical hedge, driven by e-commerce expansion and increased patient engagement with healthy aging solutions [1] - Management expressed cautious optimism that foundational work completed in 2025 has positioned the company to reaccelerate procedure revenue growth in the second half of 2026 [1]

NASDAQ:ANIX March 10, 2026 Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences' current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to iden ...

Core Viewpoint - The article introduces a new event called DEMO Z, which is a unique closed-door roadshow designed for deep discussions between investors and project decision-makers, focusing on efficiency and precision in matching investment opportunities [8][12]. Group 1: Event Overview - DEMO Z is a 30-minute deep roadshow format that allows for direct conversations with decision-makers, differing from traditional roadshows [8]. - The event is scheduled for March 18, 2026, at the Air China Century Building in Beijing, featuring five selected projects in the healthcare sector [9][16]. Group 2: Featured Projects - **Shenzhen Feimiao Medical Technology Co., Ltd.**: Focuses on advanced femtosecond laser systems for eye surgery, with a strong team from prestigious institutions and a growing market for myopia surgeries [17]. - **Beijing Zhuocheng Huisheng Biotechnology Co., Ltd.**: A leading company in infectious disease diagnostics, offering over 800 PCR testing solutions and holding 14 Class III medical device certifications [19]. - **Shanghai Fei'ershao Ackerman Biotechnology Co., Ltd.**: A pioneer in digital pathology solutions, providing services to over 500 hospitals and achieving over 100 million in revenue for four consecutive years [21][22]. - **Beijing Hope Group Biotechnology Co., Ltd.**: A leader in third-generation sequencing technology, significantly contributing to genomics and clinical diagnostics [24][25]. - **Beijing Yisheng Biotechnology Co., Ltd.**: Focuses on stem cell therapy for diabetes, with promising preclinical results and plans to initiate clinical research soon [27][28].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 要全面理解细胞生命活动的规则，我们必须了解细胞 随时间和空间变化 （4D） 的完整定量特征，以及细胞内部的化学和物理过程如何协同作用来驱 动细胞状态的变化。 目前，任何单一实验都无法同时确定整个细胞的分子组成和结构，但在细胞状态的计算建模方面已取得重大进展，同时也有越来越多的努力将不断增 长的大量生物数据集串联起来，利用机器学习 （ML） 和人工智能 （AI） 形成细胞状态的快照。以这种方式整合定量生物数据，有望预测细胞在其 生命周期不同时间点的完整分子环境。然而，利用 ML 或 AI 方法预测细胞状态的快照 （包括分子组成和物理特征） ，只是对可能结果的抽样，无法 揭示导致细胞状态随时间变化的潜在生物、化学和物理过程。 2026 年 3 月 9 日， 伊利诺伊大学厄巴纳-香槟分校的研究人员在国际顶尖学术期刊 Cell 上发表了题为： Bringing the genetically minimal cell to life on a computer in 4D 的研究论文。 该研究成功在计算机上建立了一个包含空间和时间的" 4D 全细胞模型 " （ 4DWCM ） ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 36.60, indicating a potential upside of 65.5% from the current price of HKD 22.12 [2][10]. Core Insights - The company is expected to see a recovery in product sales in the second half of 2025, achieving sustainable profitability for the year. Key catalysts for 2026 include a rebound in oncology/immunology revenue, progress in early clinical trials for ATTC, and significant results from two Phase III trials for Savolitinib [3][6]. - The company’s oncology/immunology business is projected to generate revenue between USD 330 million and USD 450 million in 2026, with a notable rebound in sales expected [6]. - The report highlights the anticipated breakthroughs for the ATTC platform, with several candidates entering clinical trials and potential business development opportunities arising from early clinical data [6]. Financial Projections - Revenue forecasts for 2026 are updated to RMB 645 million, reflecting a 1% increase from previous estimates. The gross profit is projected at RMB 301 million, with a gross margin of 46.7% [5][11]. - The net profit for 2026 is estimated at RMB 56 million, a decrease of 34% from prior forecasts, with a net profit margin of 8.7% [5][11]. - The company is expected to maintain a strong cash position, with cash and cash equivalents projected to be RMB 56 million by the end of 2026 [11][12]. Market Performance - The stock has shown a year-to-date increase of 7.27%, with a 52-week high of HKD 30.55 and a low of HKD 19.08 [5][10]. - The report indicates a significant rebound in sales for the company's products, particularly in overseas markets, with sales of Furmonertinib expected to reach USD 203 million in 2H25, reflecting a 25% increase from the previous half [6]. Valuation - The DCF valuation model estimates the equity value at approximately HKD 36.60 per share for the end of 2026, based on projected free cash flows and a perpetual growth rate of 3% [7]. - The enterprise value is calculated to be approximately USD 4.093 billion, with a net cash position of USD 1.377 billion [7]. Summary of Key Financial Metrics - The company is expected to achieve an EBIT of RMB 18 million in 2026, with a projected EBIT margin of 2.7% [11][12]. - The report outlines a gradual improvement in profitability, with net profit expected to rise to RMB 125 million by 2028, reflecting a net profit margin of 15.4% [11].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 36.60, indicating a potential upside of 65.5% from the current price of HKD 22.12 [2][10]. Core Insights - The company is expected to see a recovery in product sales in the second half of 2025, achieving sustainable profitability for the year. Key catalysts for 2026 include a rebound in oncology/immunology revenue, progress in early clinical trials for ATTC, and significant Phase III results for Savolitinib [3][6]. - The report highlights that the company's oncology/immunology business revenue is projected to reach USD 330-450 million in 2026, with a notable rebound in sales expected [6]. Financial Forecast Changes - Revenue forecasts for 2026 have been adjusted to RMB 645 million, reflecting a 1% increase from previous estimates. The gross profit is forecasted at RMB 301 million, a slight decrease of 2% from prior estimates [5][11]. - The net profit forecast for 2026 has been revised down to RMB 56 million, a 34% decrease from previous estimates, with a net profit margin of 8.7% [5][11]. Sales Performance - In the second half of 2025, the company's oncology product revenue is expected to show a significant rebound, with a 16% increase compared to the first half of 2025. Specifically, sales of Furmonertinib are projected to reach USD 203 million, with year-on-year and quarter-on-quarter increases of 22% and 25%, respectively [6][11]. - The report notes that the sales in the Chinese market are also expected to grow, with a 21% quarter-on-quarter increase in the second half of 2025 [6]. Valuation Model - The DCF valuation model estimates the equity value of the company at approximately HKD 36.60 per share for the end of 2026, based on projected free cash flows and a perpetual growth rate of 3% [7][10].

Core Viewpoint - The article discusses the volatility in global energy prices and its impact on risk assets, highlighting the influence of geopolitical events and market reactions to news from G7 meetings and statements from President Trump [1][4][5]. Group 1: Market Reactions - Oil prices surged nearly 30% to approach $120 due to concerns over supply chain disruptions, but later fell significantly after G7's commitment to stabilize prices and Trump's comments on the war's progress [3][6][29]. - U.S. stock indices experienced a strong recovery after initial declines, with the S&P 500 rising 0.8% and the Russell 2000 gaining 1.12% [2][19]. - The volatility in the market was exacerbated by retail investors' behavior and the structure of the options market, leading to significant intraday price swings [11][12]. Group 2: Economic Indicators - The 10-year U.S. Treasury yield ended a five-day rise, dropping 2.7 basis points, indicating a shift in investor sentiment as inflation concerns eased [15]. - The dollar index initially rose nearly 0.8% but later retraced all gains, reflecting market uncertainty [15][28]. - Gold prices faced pressure during the sell-off but rebounded as the dollar weakened, while silver prices increased by over 3% [17][30]. Group 3: Sector Performance - The semiconductor ETF led gains among U.S. sector ETFs, rising over 3.6%, while the energy sector saw a decline of more than 0.4% [19][21]. - The "Magnificent 7" index of major U.S. tech stocks rose 1.34%, driven by positive sentiment following Trump's remarks [23].

Core Insights - The biotechnology sector remains one of the most focused themes in the global investment market, with strong growth momentum reflected in the performance of related stocks and the overall sector [1] - The Hang Seng Biotechnology Index, launched in 2019, tracks 30 of the largest biotechnology companies listed in Hong Kong and has seen a significant increase of 64.5% in 2025, with an additional rise of 10.7% year-to-date as of February 24, 2026 [1] Group 1: Market Performance - The Hang Seng Biotechnology Index has a weight distribution of approximately 50% for biotechnology companies and 40% for pharmaceutical companies, with additional representation from drug distribution (6%) and medical devices (4%) [1] - The number of biotechnology and healthcare companies listed in Hong Kong has exceeded 270, with a total market capitalization of over HKD 4.2 trillion, showing substantial growth since the end of 2018 [2] Group 2: Investment Tools - The Hong Kong Stock Exchange offers a diverse range of investment and risk management tools in the biotechnology sector, including stocks, ETFs, structured products, and derivatives [2] - As of the end of February 2026, there are 10 ETFs tracking the Hang Seng Biotechnology Index, with a total asset management scale of HKD 15.6 billion, and the number of structured products linked to biotechnology stocks has increased from 132 in January 2025 to 500 in January 2026 [2] Group 3: Derivative Instruments - The introduction of the Hang Seng Biotechnology Index futures in November 2025 provides investors with more options for participation and risk management in the biotechnology sector [3] - Each futures contract has a contract multiplier of HKD 50 per index point, meaning a 100-point change in the index results in a contract value change of HKD 5,000 [3] Group 4: Volatility and Risk Management - The annualized volatility of the Hang Seng Biotechnology Index was approximately 41.2% for the 12 months ending January 2026, significantly higher than the Hang Seng Index (24.2%) and the Hang Seng China Enterprises Index (25.9%) [4] - Investors can use the Hang Seng Biotechnology Index futures in conjunction with biotechnology ETFs or stocks to manage overall sector risk, allowing for hedging while maintaining long-term positions [4]

Investment Rating - The report assigns an "Overweight" rating to Innovent Biologics (01801) with a target price of HKD 130 [1] Core Insights - The Chinese biotechnology sector is entering a turning point this year, with fundamentals stabilizing and innovation resilience [1] - There is ongoing licensing activity and a recovery in financing activities, although the first half of the year is characterized by a scarcity of catalysts and limited high-conviction investment themes [1] - Geopolitical uncertainties are expected to lead to a broader rotation away from high-beta sectors like biotechnology, which may face greater allocation pressure [1] - The report anticipates that the Chinese biotechnology sector will experience range-bound fluctuations in the first half of the year, with clearer price direction expected in the second half due to catalysts, capital reallocation, and more favorable valuations [1] - The next growth phase is likely to begin with significant data releases, business development activities, and increased visibility in licensing transactions, with most events concentrated in the second half of 2026 [1] - The expectation is for continued volatility driven by events in the first half, followed by a more sustained upward trend in the second half as catalysts accumulate and overseas capital flows increase [1]

Core Viewpoint - Morgan Stanley has initiated coverage on Innovent Biologics (01801) with an "Overweight" rating and a target price of HKD 130, indicating a positive outlook for the company in the context of the Chinese biotechnology sector's stabilization and resilience in innovation fundamentals [1] Industry Summary - The Chinese biotechnology sector is entering a turning point this year, with fundamentals stabilizing and ongoing licensing deals, alongside a recovery in financing activities [1] - Despite a scarcity of catalysts in the first half of the year, there are limited high-conviction investment themes, and risk appetite remains unstable [1] - Increased geopolitical uncertainties are expected to lead to a broader rotation away from high-beta sectors, with biotechnology facing greater allocation pressure [1] - The sector is anticipated to experience range-bound fluctuations in the first half of the year, driven by events, while the second half is expected to establish a clearer price direction due to accumulating catalysts and increased foreign capital flows [1] Company Summary - The next growth phase for the company may begin with significant data releases, business development activities, and increased visibility in licensing deals, with most events concentrated in the second half of 2026 [1] - Further industry re-evaluation is expected to be delayed rather than interrupted, as the company prepares for a more sustained upward trend in the second half of the year [1]